A Phase I Study of Amrubicin and Fixed Dose of Irinotecan (CPT-11) in Relapsed Small Cell Lung Cancer: Japan Multinational Trial Organization LC0303-Reference-Cited by-同舟云学术

A Phase I Study of Amrubicin and Fixed Dose of Irinotecan (CPT-11) in Relapsed Small Cell Lung Cancer: Japan Multinational Trial Organization LC0303

Published:2012-12 Issue:12 Volume:7 Page:1845-1849
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kawahara Masaaki,Kubo Akihito,Komuta Kiyoshi,Fujita Yuka,Sasaki Yoshiaki,Fukushima Masanori,Daimon Takashi,Furuse Kiyoyuki,Mishima Michiaki,Mio Tadashi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Current status of clinical trials for small cell lung cancer;Fischer;Rev Recent Clin Trials,2008

3. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America;Janne;Cancer,2002

4. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress;Chute;J Clin Oncol,1999

5. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer;Ettinger;Semin Oncol,2001

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;BMC Cancer;2021-07-05

2. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;2020-08-21

3. Dose-finding designs for trials of molecularly targeted agents and immunotherapies;Journal of Biopharmaceutical Statistics;2017-02-06